Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.
Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A. Saraceni F, et al. Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. Epub 2016 Sep 26. Bone Marrow Transplant. 2017. PMID: 27668760 No abstract available.
Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D, Chiarucci M, Poloni A, Saraceni F, Mancini G, Trappolini S, Troiani E, Montanari M, Scortechini I, Offidani M, Rupoli S, Scortechini AR, Gini G, Discepoli G, Leoni P, Olivieri A. Capelli D, et al. Among authors: saraceni f. Biol Blood Marrow Transplant. 2014 Sep;20(9):1399-406. doi: 10.1016/j.bbmt.2014.05.019. Epub 2014 May 28. Biol Blood Marrow Transplant. 2014. PMID: 24880020 Free article. Clinical Trial.
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.
Saraceni F, Labopin M, Gorin NC, Blaise D, Tabrizi R, Volin L, Cornelissen J, Cahn JY, Chevallier P, Craddock C, Wu D, Huynh A, Arcese W, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). Saraceni F, et al. J Hematol Oncol. 2016 Sep 2;9(1):79. doi: 10.1186/s13045-016-0314-x. J Hematol Oncol. 2016. PMID: 27589849 Free PMC article.
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation). Lanza F, et al. Among authors: saraceni f. Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. Am J Hematol. 2017. PMID: 28612372 Free article. No abstract available.
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.
Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A. Olivieri J, et al. Among authors: saraceni f. Bone Marrow Transplant. 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12. Bone Marrow Transplant. 2018. PMID: 29330395 Free article.
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course. Olivieri J, et al. Among authors: saraceni f. Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29. Biol Blood Marrow Transplant. 2018. PMID: 29857196 Free article.
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, Aljurf M, Bruno B, Pioltelli P, Passweg J, Sociè G, Santarone S, Yakoub-Agha I, Lanza F, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Saraceni F, et al. Am J Hematol. 2018 Oct;93(10):1211-1219. doi: 10.1002/ajh.25225. Epub 2018 Aug 15. Am J Hematol. 2018. PMID: 30033639 Free article.
40 results